Liliang P. Xia

West Huaihai Road 241
Huaihai, 200030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Author Correction: A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice.

Author Correction: A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice.

Journal: Nature microbiology

Published: June 16, 2026

BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer.

BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer.

Journal: Journal for immunotherapy of cancer

Published: April 18, 2025

A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice.

A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice.

Journal: Nature microbiology

Published: March 23, 2025

Single-cell spatial proteomics of non-relapse small cell lung cancer identifies tumor microenvironment determinants of survival.

Single-cell spatial proteomics of non-relapse small cell lung cancer identifies tumor microenvironment determinants of survival.

Journal: Cell biology and toxicology

Published: February 27, 2025

Preparation and characterization of a Llama VHH-hFc chimeric antibody recognizing conserved neutralization epitope of H5N1 hemagglutinin with high affinity.

Preparation and characterization of a Llama VHH-hFc chimeric antibody recognizing conserved neutralization epitope of H5N1 hemagglutinin with high affinity.

Journal: Archives of microbiology

Published: December 13, 2024

PTPRT loss enhances anti-PD-1 therapy efficacy by regulation of STING pathway in non-small cell lung cancer.

PTPRT loss enhances anti-PD-1 therapy efficacy by regulation of STING pathway in non-small cell lung cancer.

Journal: Science translational medicine

Published: September 04, 2024

EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.

EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.

Journal: Journal of translational medicine

Published: April 16, 2024

EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment.

EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 03, 2024

Cisplatin-induced Pyroptosis Enhances the Efficacy of PD-L1 Inhibitor in Small-Cell Lung Cancer via GSDME/IL12/CD4Tem Axis.

Cisplatin-induced Pyroptosis Enhances the Efficacy of PD-L1 Inhibitor in Small-Cell Lung Cancer via GSDME/IL12/CD4Tem Axis.

Journal: International journal of biological sciences

Published: August 12, 2023

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study.

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study.

Journal: Journal of clinical medicine

Published: October 24, 2022

A 3D Ex Vivo Tumor-Immune Coculture System Mimicking In Vivo Tumor Environmental Stress on CD8+ T Cells Exhaustion.

A 3D Ex Vivo Tumor-Immune Coculture System Mimicking In Vivo Tumor Environmental Stress on CD8+ T Cells Exhaustion.

Journal: Advanced biology

Published: September 21, 2022

Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment.

Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment.

Journal: Journal of clinical medicine

Published: June 07, 2022

Showing 1-12 of 26

Last Updated: 09/26/2026